2024-11-20 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a leading healthcare company producing medical devices, pharmaceuticals, and consumer health products, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ showed a cumulative return of 34.15%, VOO achieved a return of 125.6%. This represents a substantial lag of -91.45%.  The relative divergence of -91.45% places JNJ in the 2.54th percentile of its historical performance relative to the S&P 500, indicating consistent underperformance.  The provided CAGR data further supports this, showing JNJ's growth consistently below the market's, especially in recent years (2021-2024).

**2. Recent Price Movement:**

* **Closing Price:** $153.0 (Last Market: $152.97)
* **5-Day Moving Average:** $153.38
* **20-Day Moving Average:** $157.7
* **60-Day Moving Average:** $161.6

The price is currently below all three moving averages, suggesting a bearish trend in the short to medium term.

**3. Technical Indicators and Expected Return:**

* **RSI (25.24):**  Indicates the stock is in oversold territory, potentially suggesting a bounce is possible, but not necessarily a strong buy signal.
* **PPO (-0.25):**  Negative PPO confirms the bearish sentiment, indicating weakening momentum.
* **20-Day Relative Divergence (-4.25):** Shows a recent decline in relative performance against the S&P 500.
* **Expected Return (0.0%):** The expected return is currently 0%, meaning no significant outperformance relative to the S&P 500 is anticipated in the long term (2+ years), based on the provided data. This is consistent with the historical underperformance.
* **Price Note:** The closing price of $152.97 is close to the 5-day moving average. The fact that it is not significantly higher does not indicate any significant sudden upward or downward movement.

**4. Recent Earnings and Outlook:**

The provided earnings data shows some volatility in EPS and relatively stable revenue around $22 Billion.  There is no provided estimate for the most recent quarter (2024-10-23) to compare the actual results against.  A deeper dive into the underlying factors driving EPS fluctuations is needed for a comprehensive assessment of the companyâ€™s performance.

**5. Financial Information:**

* **Revenue and Profitability:** Shows consistent high profit margins (around 69%) despite some fluctuations in revenue.
* **Capital and Profitability:** ROE is volatile, with a significant spike in 2023-09-30. Further analysis is needed to understand the causes of these fluctuations.


**6. News and Recent Issues:**

* *(This section requires input. Please provide recent news articles (from sources like Shacknews, FINBOLD, etc.) for analysis.  Specifically, information on recent earnings announcements, analyst opinions, and the overall market outlook for JNJ is needed to complete this section.)*


**7. Summary of Analysis:**

JNJ has significantly underperformed the S&P 500 in recent years.  Technical indicators suggest a bearish short-term outlook, while the RSI hints at potential oversold conditions.  Long-term prospects remain uncertain, with no significant outperformance expected compared to the S&P 500 based on the current data.  A more detailed analysis requires a review of recent news and a deeper investigation into the reasons for fluctuations in EPS and ROE.  The consistent high profit margins are a positive indicator, however, the significant underperformance compared to market averages raises significant concerns.


**8. Recommendation:**

Based on the limited information provided and the observed underperformance relative to the market, a cautious approach is recommended.  Further research is needed, including a thorough review of recent news, analyst reports and a detailed financial statement analysis before making any investment decision.  The relatively stable revenue and high profit margins suggest inherent value but the consistent underperformance demands further scrutiny before any long-term investment strategy is pursued.
